Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 43, Issue 8, Pages 686-700Publisher
CELL PRESS
DOI: 10.1016/j.tips.2022.04.002
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R00 CA240896]
- Cancer Research Foundation Young Investigator Award
- Lynn Sage Scholar Award
- American Cancer Society [IRG-21-144-27]
- Bill Bass Foundation
- Northwestern University start-up funds
- Robert H. Lurie Comprehensive Cancer Center
- Department of Defense (DoD) Career Development [W81XWH-21-1-0380]
Ask authors/readers for more resources
Glioblastoma (GBM) is a common and lethal brain tumor, and the symbiotic interaction between immune cells and GBM cells plays a critical role in tumor progression and therapy resistance. Targeting the tumor-immune symbiosis pharmacologically has emerged as a promising strategy for GBM treatment.
Glioblastoma (GBM) is the most common and highly lethal form of primary brain tumor in adults. The median survival of GBM patients is approximately 14-16 months despite multimodal therapies. Emerging evidence has substantiated the critical role of symbiotic interactions between GBM cells and noncancerous immune cells (e.g., myeloid cells and T cells) in regulating tumor progression and therapy resistance. Approaches to target the tumor-immune symbiosis have emerged as a promising therapeutic strategy for GBM. Here, we review the recent developments for pharmacological targeting of the GBM-immune symbiosis and highlight the role of such strategies to improve the effectiveness of immunothera-pies in GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available